My GLP-1 Wears Off Mid-Week — Is That Normal?

It is one of the most common things people notice on a weekly GLP-1: the appetite suppression feels strong for the first few days after the shot, then seems to fade in the day or two before the next dose. You start wondering whether the drug is “wearing off,” whether you should split the dose, or whether you have already built up a tolerance. This guide walks through the actual pharmacology — why semaglutide and tirzepatide are dosed weekly in the first place, why a mid-week dip is more noticeable early in treatment and at low doses, and how to tell the difference between true tolerance and simply not being at an effective dose yet. The short version: a mild mid-week dip is common, usually improves at steady state and higher doses, and is a conversation to have with your prescriber — not a reason to start self-adjusting your schedule.

TL;DR — is a mid-week dip normal?

• Yes, a mild dip is common — especially early. Weekly GLP-1s are designed to hold relatively steady blood levels across the week, but appetite is influenced by more than drug concentration, and some people genuinely notice hunger returning in the last day or two.
• It usually improves with time and dose. The “wear-off” feeling tends to be strongest in the first weeks and at the starter doses, before levels reach steady state and before you are at a dose that fully controls appetite.
• A returning appetite is often “not yet at an effective dose,” not tolerance. These two feel similar but mean very different things — and only one of them is a signal to titrate up.
• Do not split or move your dose on your own. Switching to twice-weekly dosing or changing your injection day is an off-label change to a clinically studied schedule; it belongs in a prescriber conversation, not a DIY experiment.
• Talk to your prescriber. Persistent mid-week hunger is exactly the kind of observation that helps your prescriber decide whether it is time for a titration step.

Why GLP-1s are dosed once a week

The whole point of a long-acting weekly GLP-1 is to avoid the peaks and troughs you would get with a short-acting drug. Native GLP-1 (the gut hormone these medicines mimic) has a half-life measured in minutes — it is broken down almost immediately by the enzyme DPP-4. Semaglutide and tirzepatide are engineered to resist that breakdown and to bind to albumin, a carrier protein in the blood, which dramatically slows their clearance.

The result is a very long half-life. For semaglutide, the FDA Wegovy label and the population-pharmacokinetic analysis by Overgaard et al.^[3] put the elimination half-life at roughly 1 week (about 7 days). For tirzepatide, the Zepbound label and the phase 1 pharmacokinetic work by Furihata et al.^[4] put it at approximately 5 days. A half-life that long is precisely what makes once-weekly dosing possible: by the time the next dose is due, only a fraction of the previous dose has cleared.

Flat levels vs the peak-to-trough you can feel

Here is the apparent contradiction: if weekly levels are “relatively flat,” why do so many people feel a dip? Two reasons.

First, “relatively flat” is not “perfectly flat.” Even with a long half-life, blood concentration does peak in the day or two after your injection and reach its lowest point (the trough) just before the next dose. The size of that peak-to-trough swing depends on the half-life: semaglutide's longer ~7-day half-life produces a smaller swing, while tirzepatide's ~5-day half-life produces a slightly larger one. Neither drug crashes between doses, but the trough is real, and for some people that trough lines up with the return of hunger.

Second, appetite is not a pure readout of drug level. How hungry you feel on any given day is shaped by sleep, stress, your menstrual cycle, activity, what you ate the day before, and plain expectation. A hungry Thursday is not proof that the drug “ran out” — it may simply be a hungry Thursday. The mid-week dip is best thought of as a combination of a genuine (small) pharmacologic trough and a lot of normal day-to-day variation layered on top.

Why the dip is more noticeable early and at low doses

Two things change as you progress through treatment, and both reduce the wear-off feeling.

1. You haven't reached steady state yet

With a drug this long-acting, your blood level does not reach its stable plateau after a single dose. It takes roughly four to five half-lives of repeated weekly dosing to reach steady state — about 4–5 weeks for semaglutide and a few weeks for tirzepatide. Until then, each week's peak and trough are both still climbing toward their eventual stable values. In those early weeks the trough is genuinely lower relative to where it will eventually settle, so a late-week dip is more likely to be felt. As you reach steady state, the whole week's curve lifts and stabilizes, and the dip tends to soften.

2. Starter doses are tolerability ramps, not therapeutic doses

The lowest doses on the ladder (semaglutide 0.25 mg; tirzepatide 2.5 mg) exist to let your gut adjust — they are explicitly initiation doses in the FDA labels, not the doses that produced the headline weight-loss numbers. The STEP-1 trial^[1] reached its ~14.9% mean weight loss at the 2.4 mg maintenance dose of semaglutide, and SURMOUNT-1^[2] reached up to ~20.9% at the 15 mg maintenance dose of tirzepatide — not at the starter steps. So if you are early in titration and feeling hunger creep back before your next shot, the most likely explanation is simply that you are not yet at a dose that fully suppresses appetite for the whole week. That is expected, and it usually improves as you step up.

True tolerance vs not-yet-at-an-effective-dose

This is the distinction that matters most, because the two feel almost identical — appetite returning — but they point to opposite conclusions.

• “Not yet at an effective dose” means the dose you are on was never strong enough to control your appetite across the full week. You feel good for a few days, then hunger returns. The fix is usually a planned titration step up — the medicine is working, you just need more of it. This is by far the most common reason for a mid-week dip in the first months.
• True tolerance (tachyphylaxis) means a dose that was reliably controlling your appetite gradually stops doing so over weeks to months, even though nothing else changed. Genuine pharmacologic tolerance to GLP-1s is far less established than people assume; what often gets called “tolerance” is really a normal weight-loss plateau (your body reaching a new equilibrium) rather than the drug losing potency.

A practical way to tell them apart: ask whether this dose ever fully controlled your appetite for a whole week. If it never did, you are likely under-dosed, not tolerant. If a dose worked well for months and then clearly faded, that is worth a closer look with your prescriber — but even then, a plateau in the number on the scale is usually equilibrium, not failure. For more on plateaus versus dose adequacy, see our guide on when to increase your tirzepatide dose for weight loss.

When mid-week hunger means you're ready to titrate up

A returning appetite before your next dose is one of the more useful signals your prescriber can act on. In general, the conditions that make a titration step reasonable are:

1. You've been at the current dose long enough. The FDA labels for both drugs specify a minimum of 4 weeks at each step before increasing, to allow steady state and side-effect stabilization.
2. Appetite control is incomplete — including that late-week dip. If hunger is consistently breaking through before your next shot and you are not seeing the response you want, that is a classic reason to discuss going up.
3. Your GI side effects are manageable. Nausea and other GI effects are dose-dependent; the right time to step up is when the current dose is well tolerated.
4. Your prescriber agrees. Dose escalation is a clinical decision that weighs your full picture, not a self-adjustment.

Bring the specifics to your appointment: which day the hunger returns, how strong it is, and whether your side effects have settled. That detail is far more useful than “it feels like it wears off.”

Why you shouldn't split or move your dose on your own

When the mid-week dip is annoying, two DIY fixes circulate online: splitting the weekly dose into two smaller twice-weekly injections, or shifting the injection day earlier. Both are changes to a clinically validated schedule, and both should run through your prescriber first.

• Twice-weekly splitting is not the studied regimen. The STEP-1^[1] and SURMOUNT-1^[2] trials — and the FDA labels — are built entirely on once-weekly dosing. There is no approved twice-weekly schedule for these drugs, and because the half-lives are long (~7 days for semaglutide, ~5 for tirzepatide), the theoretical benefit of splitting is modest while the risk of dosing errors is real. People most likely to encounter custom split schedules are those on compounded products; if that is you, see our explainer on how to read a compounded GLP-1 dose and follow your provider's instructions exactly.
• Moving your dose day changes your interval. The FDA labels allow some flexibility — for instance, the day of weekly administration can be changed if needed, as long as a minimum gap between doses is respected — but doing this casually can shorten or lengthen your interval and confuse the schedule. The rules differ by drug; our guide to missed-dose rules by drug covers what each label actually permits.
• “Microdosing” is a different conversation entirely. Deliberately using very low doses (for maintenance or tolerability) is sometimes discussed, but it is off-label and unstudied for that purpose. If it is on your mind, read our evidence reviews on semaglutide microdosing and tirzepatide microdosing — and raise it with your prescriber rather than improvising.

The unifying point: your dose and schedule were chosen for reasons that include your tolerability, your goals, and what has actually been tested in trials. Changing them on your own removes the clinical judgment that makes them safe.

What the maintenance trials tell us about steady control

If weekly dosing genuinely controlled appetite, you would expect that staying on it keeps weight off — and that stopping it brings appetite and weight back. That is exactly the pattern the maintenance trials show, which is reassuring evidence that the weekly schedule does its job when you stay on an effective dose.

• In the STEP-4 trial^[5], people who continued weekly semaglutide after a run-in period kept losing weight, while those switched to placebo regained — demonstrating that the ongoing weekly dose, not a one-time effect, was doing the work.
• In the STEP-1 extension^[6], stopping semaglutide led to a return of appetite and substantial weight regain over the following year — consistent with a chronic condition that the weekly medicine manages rather than cures.

The relevance to your mid-week dip: these trials confirm that the appetite control comes from sustained weekly exposure at an adequate dose. A small late-week dip within that sustained exposure is a minor ripple on a curve that, at steady state and an effective dose, holds appetite down across the week.

Frequently asked questions

Related research

• When to increase your Mounjaro (tirzepatide) dose for weight loss — the four conditions that signal a titration step is appropriate, and the four that say hold
• GLP-1 missed-dose rules by drug — what each FDA label permits for late, missed, or shifted doses
• Semaglutide microdosing evidence guide — what the evidence does and doesn't say about very low doses
• Tirzepatide microdosing evidence guide — the same evidence-first look for tirzepatide
• How to read a compounded GLP-1 dose — decoding concentrations, units, and custom schedules on compounded products

Medical disclaimer. This article is for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Half-life and pharmacokinetic figures are approximate and drawn from FDA prescribing information and the cited pharmacokinetic studies; individual responses vary. A mild mid-week change in appetite is common and is not on its own a reason to change your dose, your injection day, or your schedule. Do not split doses, switch to twice-weekly dosing, change your dosing day, or escalate your dose without explicit guidance from your prescriber, who can weigh your full clinical picture. Every primary source cited here was verified against the live PubMed E-utilities API on 2026-06-28.